Antiplatelet Therapy Overview for PTCB Exam Preparation
Study antiplatelet medications including aspirin, clopidogrel, and newer agents. Essential cardiovascular pharmacology for the PTCB exam.
Understanding Antiplatelet Therapy
Antiplatelet medications prevent blood clots by inhibiting platelet activation and aggregation. These drugs are cornerstone treatments for cardiovascular disease and are high-yield topics for the PTCB exam.
Aspirin
Aspirin irreversibly inhibits cyclooxygenase (COX), blocking thromboxane A2 production. Low-dose aspirin (81 mg daily) is widely used for cardiovascular prevention. Pharmacy technicians should know that aspirin's antiplatelet effect lasts the lifetime of the platelet (7 to 10 days), which is why it must be discontinued before surgical procedures.
P2Y12 Receptor Inhibitors
These medications block the P2Y12 adenosine diphosphate receptor on platelets:
- Clopidogrel (Plavix) is the most commonly prescribed, requiring hepatic activation
- Prasugrel (Effient) has faster onset and more potent platelet inhibition
- Ticagrelor (Brilinta) is a reversible inhibitor taken twice daily
Dual Antiplatelet Therapy (DAPT)
After coronary stent placement or acute coronary syndrome, patients typically receive both aspirin and a P2Y12 inhibitor. The duration of DAPT ranges from 1 to 12 months depending on the clinical scenario and stent type.
Key Counseling Points
- Report unusual bleeding or bruising to a healthcare provider immediately
- Avoid concurrent use of NSAIDs, which can increase bleeding risk
- Ticagrelor must be taken with low-dose aspirin (81 mg) only
- Do not stop antiplatelet therapy without consulting a prescriber
Cardiovascular medications are heavily tested on the PTCB exam. Master them with our drug flashcards and full-length practice exams.
Ready to ace the PTCE?
Practice with 800+ flashcards, 40 mini exams, and 10 full-length PTCE simulations.
Start Free